Cancer biology - Signatures guide drug choice

被引：46

作者：

Downward, J ^{[1
]}

机构：

[1] Canc Res UK London Res Inst, London WC2A 3PX, England

来源：

NATURE | 2006年 / 439卷 / 7074期

关键词：

D O I：

10.1038/439274a

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Cancer drugs are increasingly designed to target specific cell-signalling pathways. When, and in what combination, these drugs should be used might be judged by analysing the gene expression signature of the tumour.

引用

页码：274 / 275

页数：2

共 10 条

[1] Oncogenic pathway signatures in human cancers as a guide to targeted therapies [J].

Bild, AH ;

Yao, G ;

Chang, JT ;

Wang, QL ;

Potti, A ;

Chasse, D ;

Joshi, MB ;

Harpole, D ;

Lancaster, JM ;

Berchuck, A ;

Olson, JA ;

Marks, JR ;

Dressman, HK ;

West, M ;

Nevins, JR .

NATURE, 2006, 439 (7074) :353-357

[2] Targeting ras signalling pathways in cancer therapy [J].

Downward, J .

NATURE REVIEWS CANCER, 2003, 3 (01) :11-22

[3] Gene expression phenotypic models that predict the activity of oncogenic pathways [J].

Huang, E ;

Ishida, S ;

Pittman, J ;

Dressman, H ;

Bild, A ;

Kloos, M ;

D'Amico, M ;

Pestell, RG ;

West, M ;

Nevins, JR .

NATURE GENETICS, 2003, 34 (02) :226-230

[4] Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression [J].

Mao, JH ;

To, MD ;

Perez-Losada, J ;

Wu, D ;

Del Rosario, R ;

Balmain, A .

GENES & DEVELOPMENT, 2004, 18 (15) :1800-1805

[5] Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius [J].

Neiman, PE ;

Ruddell, A ;

Jasoni, C ;

Loring, G ;

Thomas, SJ ;

Brandvold, KA ;

Lee, RM ;

Burnside, J ;

Delrow, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (11) :6378-6383

[6] Microarray expression profiling in melanoma reveals a BRAF mutation signature [J].

Pavey, S ;

Johansson, P ;

Packer, L ;

Taylor, J ;

Stark, M ;

Pollock, PM ;

Walker, GJ ;

Boyle, GM ;

Harper, U ;

Cozzi, SJ ;

Hansen, K ;

Yudt, L ;

Schmidt, C ;

Hersey, P ;

Ellem, KAO ;

O'Rourke, MGE ;

Parsons, PG ;

Meltzer, P ;

Ringnér, M ;

Hayward, NK .

ONCOGENE, 2004, 23 (23) :4060-4067

[7] Targeting the mitogen-activated protein kinase cascade to treat cancer [J].

Sebolt-Leopold, JS ;

Herrera, R .

NATURE REVIEWS CANCER, 2004, 4 (12) :937-947

[8] BRAF mutation predicts sensitivity to MEK inhibition [J].

Solit, DB ;

Garraway, LA ;

Pratilas, CA ;

Sawai, A ;

Getz, G ;

Basso, A ;

Ye, Q ;

Lobo, JM ;

She, YH ;

Osman, I ;

Golub, TR ;

Sebolt-Leopold, J ;

Sellers, WR ;

Rosen, N .

NATURE, 2006, 439 (7074) :358-362

[9] An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis [J].

Sweet-Cordero, A ;

Mukherjee, S ;

Subramanian, A ;

You, H ;

Roix, JJ ;

Ladd-Acosta, C ;

Mesirov, J ;

Golub, TR ;

Jacks, T .

NATURE GENETICS, 2005, 37 (01) :48-55

[10] Cancer: Addiction to oncogenes - The Achilles heal of cancer [J].

Weinstein, IB .

SCIENCE, 2002, 297 (5578) :63-64

← 1 →